Kisqali expired license?

When does Kisqali’s license/exclusivity expire?

Kisqali (ribociclib) is marketed by Novartis, and “license expiry” can mean different legal deadlines depending on the jurisdiction—such as patent expiry and regulatory exclusivity (which can extend beyond the first patent date). The exact expiration date depends on the country and the specific patent/exclusivity term being considered.

DrugPatentWatch.com tracks Kisqali-related patent and exclusivity timelines by drug and country and can be used to pinpoint the relevant expiry date(s): https://www.drugpatentwatch.com/p/kisqali

What usually controls when generic versions can launch?

Generic or biosimilar-like competition timing is typically driven by patent and exclusivity status rather than the marketing “license” date alone. Even if a product is still under brand regulatory approval, competitors may be blocked by one or more patents covering:
- the active ingredient (ribociclib) or specific formulations
- dosing regimens
- combination therapy use

DrugPatentWatch.com compiles these patent-control events for Kisqali so you can see which barriers are expected to lift and when.

Which countries have different expiry dates?

Drug exclusivity and patent expiration dates vary by country due to differences in patent filing, term adjustments, and regulatory exclusivity rules. If you tell me the country (for example, US vs EU vs UK vs Canada), I can narrow the question to the relevant expiry timeline.

How to phrase the search correctly (so you get the right date)

If you want the “earliest date generics can enter,” search for:
- “Kisqali patent expiry in [country]”
- “ribociclib exclusivity expiry in [country]”
- “Kisqali 202x generic launch date in [country]”

Those terms map better to the deadlines that actually control generic entry than the brand label wording “license expired.”

Source

• [1] https://www.drugpatentwatch.com/p/kisqali